Detalhe da pesquisa
1.
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI.
Future Oncol
; 20(15): 969-980, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38095056
2.
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
N Engl J Med
; 383(21): 2018-2029, 2020 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207094
3.
Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.
J Gastroenterol Hepatol
; 38(8): 1381-1388, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37218373
4.
Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer.
Future Oncol
; 19(14): 961-973, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306090
5.
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Contemp Oncol (Pozn)
; 27(4): 217-223, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38405208
6.
Orientation-aware plasma cell-free DNA fragmentation analysis in open chromatin regions informs tissue of origin.
Genome Res
; 29(3): 418-427, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30808726
7.
Overcoming immunosuppression and pro-tumor inflammation in lung cancer with combined IL-1ß and PD-1 inhibition.
Future Oncol
; 18(27): 3085-3100, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36004638
8.
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Int J Cancer
; 148(9): 2313-2320, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33231285
9.
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
N Engl J Med
; 379(23): 2220-2229, 2018 12 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30280641
10.
Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection.
Am J Gastroenterol
; 116(6): 1274-1283, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33560651
11.
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma.
Invest New Drugs
; 39(5): 1375-1382, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33856599
12.
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Future Oncol
; 17(14): 1709-1719, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33569983
13.
Plain language summary of the CROWN study comparing lorlatinib with crizotinib for people with untreated non-small cell lung cancer.
Future Oncol
; 17(34): 4649-4656, 2021 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34585621
14.
Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.
Future Oncol
; 17(12): 1459-1472, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33648347
15.
The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050.
Future Oncol
; 17(7): 783-794, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33164569
16.
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Cancer
; 126(2): 373-380, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31769875
17.
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lancet
; 393(10183): 1819-1830, 2019 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30955977
18.
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 377(9): 829-838, 2017 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-28586279
19.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
N Engl J Med
; 376(7): 629-640, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27959700
20.
Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.
Future Oncol
; 15(13): 1481-1491, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30839234